RADNOSTIX, INC. 的盈利质量评分为 B+/47.830322。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
RADNOSTIX, INC. 何时发布财报?
RADNOSTIX, INC. 的下一份财报预计在 2026-02-16 发布
RADNOSTIX, INC. 的预期收益是多少?
根据华尔街分析师的预测,RADNOSTIX, INC. 的预期收益为 $
RADNOSTIX, INC. 是否超出收益预期?
RADNOSTIX, INC. 最近的收益为 $, 预期。
关键数据
前收盘价
$0.0824
开盘价
$0.08
当日区间
$0.08 - $0.08
52周范围
$0.03 - $0.11
交易量
2.7K
平均成交量
34.9K
股息收益率
--
每股收益(TTM)
-0.00
市值
$42.2M
什么是 INIS?
Radnostix, Inc. engages in the manufacture of nuclear medicine calibration and reference standards cobalt tele therapy sources, as well as radioisotopes and radiochemical for medical research and clinical devices. The company is headquartered in Idaho Falls, Idaho and currently employs 41 full-time employees. The firm manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. The firm provides contract manufacturing of various drug products as well as radioisotope active pharmaceutical ingredient (API) supply for third party theranostics clients. The firm manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and single photon emission computed tomography (SPECT)/positron emission tomography (PET) imaging systems as well as industrial calibration standards under its RadQual brand. The firm also manufactures Cobalt-60 sealed source products.